Johnson & Johnson Weighs $20 Billion Sale of Its Orthopedics Unit to Apollo
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
/ 22 items
#JNJ↓
Tyra’s SURF302 Data Missed the Street’s 70% CR Bar
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
Johnson & Johnson Cuts 2026 Earnings Outlook on $1 Billion Acquisition Costs
Johnson & Johnson cuts 2026 adjusted EPS guidance to $10.96–$11.11 after its $1B Firefly Bio acquisition and Sail Biomedicines partnership.
J&J Agrees to $5.5 Billion Settlement to End Decade of Talc Cancer Lawsuits
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
Piper Sandler: Intuitive Surgical Still Dominant in Soft-Tissue Robotics Despite J&J’s Ottava
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.